Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Icon Plc (NQ: ICLR )

214.25 +1.49 (+0.70%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Icon Plc

< Previous 1 2 3 4 5 6 Next >
Where Icon Stands With Analysts
Via Benzinga
ICON Reports First Quarter 2023 Results
From ICON plc
Via Business Wire
What 5 Analyst Ratings Have To Say About Icon
Via Benzinga
ICON plc Schedules First Quarter 2023 Earnings Conference Call
From ICON plc
Via Business Wire
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
These companies strive to bring down the cost of developing new therapies. 
Via The Motley Fool
Earnings Preview For Icon
Via Benzinga
Hopeful Golden Cross Forms On Icon's Chart
Via Benzinga
The Latest Analyst Ratings for Icon
Via Benzinga
Where Icon Stands With Analysts
Icon (NASDAQ:ICLR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Should You Bring The Luck Of The Irish To Your Investmets?
An index of Irish stocks is outperforming the S&P 500 this year, with large, U.S.-listed companies such as Ryan Air and CRH among top price performers. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Catalent Stock Showing Improved Relative Strength Rating
On Friday, Catalent stock earned a positive adjustment to its Relative Strength (RS) Rating, from 63 to 74. 
Via Investor's Business Daily
ICON plc to Present at Upcoming Investor Conferences
From ICON plc
Via Business Wire
ICON Reports Fourth Quarter and Full Year 2022 Results
From ICON plc
Via Business Wire
Where Icon Stands With Analysts
Analysts have provided the following ratings for Icon (NASDAQ:ICLR) within the last quarter: 
Via Benzinga
Analyst Ratings for Icon
Icon (NASDAQ:ICLR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The 7 Best Growth Stocks to Buy for February 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
ICON plc Schedules Fourth Quarter 2022 Earnings Conference Call
From ICON plc
Via Business Wire
ICON Issues Financial Guidance for Full Year 2023
From ICON plc
Via Business Wire
What 6 Analyst Ratings Have To Say About Icon
Icon (NASDAQ:ICLR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2023
Via Benzinga
ICON plc to Present at the 41st Annual J.P. Morgan Healthcare Conference
From ICON plc
Via Business Wire
ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others
From ICON plc
Via Business Wire
ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference
From ICON plc
Via Business Wire
Jim Cramer Says This Stock Down 25% This Year Is 'Not To Be Touched, Because They're Doing Very Poorly'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said AST SpaceMobile Inc (NASDAQ: ASTS) is an "exciting thing, not a stock. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Upgrades 
Via Benzinga
ICON Reports Third Quarter 2022 Results
From ICON plc
Via Business Wire
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. 
Via Investor's Business Daily
ICON selected by BARDA to conduct anthrax vaccine clinical trial
From ICON plc
Via Business Wire
ICON plc Schedules Third Quarter 2022 Earnings Conference Call
From ICON plc
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.